title: Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.
abstract: The World Health Organisation (WHO) classifies myeloproliferative neoplasm (MPN) into BCR-ABL positive chronic myeloid leukaemia (CML Ph(+)) and Ph(-) MPN. The JAK2 V617F mutation is specific for Ph(-) MPN and occurs in approximately 50% of primary myelofibrosis. Earlier reports suggest that the occurrence of JAK2 and BCR-ABL mutations are mutually exclusive. However, recent reports have documented the coexistence of BCR-ABL and JAK2 mutation in the same patient mostly following treatment with tyrosine kinase inhibitors (TKIs). We thus report a 60-year-old male with atypical clinical and laboratory features of MPN and the presence of both BCR-ABL and JAK2 Mutations.
authors: Department of Haematology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
authors: Abdulaziz
authors: A
authors: Hassan
authors: Department of Haematology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
authors: Livingstone Gayus
authors: LG
authors: Dogara
authors: Department of Haematology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
authors: Ahmadu Aliyu
authors: AA
authors: Babadoko
authors: Department of Haematology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
authors: Sani
authors: S
authors: Awwalu
authors: Department of Haematology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
authors: Aisha Indo
authors: AI
authors: Mamman
keywords: BCR-ABL; CML; JAK2; mutation; myelofibrosis
references: Blood. 2005 Nov 15;106(10):3370-3
references: 16037387
references: Genes Cancer. 2010 Oct;1(10):979-93
references: 21442038
references: Blood. 2005 Oct 15;106(8):2920-1
references: 16204151
references: Am J Clin Pathol. 2009 Aug;132(2):250-60
references: 19605820
references: J Coll Physicians Surg Pak. 2011 Aug;21(8):472-5
references: 21798133
references: Leuk Res. 2009 Nov;33(11):e212-3
references: 19589593
references: Lancet Oncol. 2007 Jul;8(7):658-60
references: 17613428
references: Ann Oncol. 2010 May;21 Suppl 5:v165-7
references: 20555071
references: Blood. 2006 Sep 15;108(6):1865-7
references: 16728702
references: Hepatology. 2006 Dec;44(6):1528-34
references: 17133457
references: Lancet Oncol. 2007 Oct;8(10):864-6
references: 17913657
references: Exp Hematol Oncol. 2013 Sep 05;2(1):24
references: 24007855
references: Blood. 2007 May 1;109(9):4106-7
references: 17449802
references: Leukemia. 2007 May;21(5):1103-4
references: 17301812